OncoZenge AB (publ) (STO:ONCOZ)
Sweden · Delayed Price · Currency is SEK 2.970
-0.035 (-1.16%)
Nov 4, 2026, 9:16 AM CET
OncoZenge AB Earnings Call Transcripts
Fiscal Year 2026
-
Oral mucositis remains a major unmet need for cancer patients, with current treatments often inadequate. A new bupivacaine lozenge is in phase III trials across Europe, supported by strong partnerships and recent financing, with global expansion and additional indications under consideration.